In line with this observation, the BH3-mimetic drug, ABT-199 or venetoclax, selectively binds the hydrophobic cleft of Bcl-2 with sub-nanomolar affinity [31] and prevents its anti-apoptotic effect on mitochondria, which had no significant effect on intracellular Ca2+ release in both Bcl-2-dependent cancer cells and in normal, healthy cells such as pancreatic acinar cells [32, 33]. This evidence concerns the gene BCL2 and cancer.